Regorafenib drug

«Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.[1] By 2015 it had 2 US approvals for advanced cancer(wikipedia)

  • Has Subnodes:

Pathways of Regorafenib

Textual paths of Biolinks with Validity Score > 3.0
Calculate
Uses in-app credits Help
This tool shows paths like: A B C Regorafenib

Mindmaps

Visualisation of logical biolinks between drugs, supplements, symptoms etc..

MoreVitaminovPRO ranked added it 1 year ago on Jun 18, 2019